Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies International Journal of Obesity

Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies International Journal of Obesity

Most importantly, this therapy improves mood, energy, vigor and overall quality of life. In patients with class III obesity, weight decreased from 129.0±5.6 to 98.9±4.8 kg. The changes were statistically significant for all 8 years vs previous year (Figures 2a–d; Table 2).

  • There were only two deaths in the testosterone group, and neither was related to treatment.
  • Finally, mean plasma glucose levels declined from 105.8 to 97.0 mg/dL over the 4-year period.
  • Simply, T therapy produces WL, is well -tolerated and safe, and no weight regain, and patient compliance is very high.
  • The mean length of time required for achieving azoospermia was 108 days (Gu et al., 2003).

Testosterone is available as oral testosterone undecanoate, buccal testosterone, intramuscular testosterone esters, testosterone implants, and testosterone transdermal patches and gel. Proponents of transdermal testosterone products, such as gels and scrotal or non-scrotal dermal patches, claim that they have a good safety profile [101]. Transdermal testosterone replacement certainly improves bone mass and lean body mass, reduces fat mass, and improves mood and sexual function. Acne, polycythemia, and gynecomastia are stated to be less common with this form of therapy than with the intramuscular esters. To date these claims must be regarded with some reservations; it is not at all clear that in equieffective doses the local or topical forms of administration dissociate wanted and unwanted effects.

Long-term potential, short-term squeeze – HMi meets Marlon Schramm, Christie & Co’s head of healthcare Germany

There were no major adverse cardiovascular events in the testosterone group, but there were 28 nonfatal strokes and 25 nonfatal myocardial infractions in the control group. Prostate volume increased slightly in the testosterone group, but not to any clinically meaningful degree, and stayed virtually unchanged in the control group. The male hypogonadism https://beyousalons.com/2023/09/07/cipandrol-200-mg-balkan-pharmaceuticals-impressive/ treatment has patent exclusivity in the EU until March 2024 and in the U.S. until May 2027, although it is not sold in the U.S. However, the FDA approved Aveed, a similar drug from Endo Pharmaceuticals, in 2014. This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management.

In 2018, Grünenthal acquired the European rights to Nexium™ as well as the global rights to Vimovo™ (ex-US and Japan) from AstraZeneca. Nexium helps to reduce the amount of acid produced by the stomach in patients with gastrointestinal reflux conditions and ulcers. Vimovo is amodified-release fixed-dose combination tablet of naproxen, a pain-relieving NSAID and esomeprazole, the active ingredient in Nexium, for the treatment of various inflammatory diseases. The long-acting injectable treatment for testosterone deficiency has been commercially approved in more than 80 countries. Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States. The Bayer Lighthouse Project was developed to help UK healthcare professionals identify and treat patients with hypogonadism, a condition that is under-diagnosed and under-treated by clinicians.

Switzerland: Swiss Medical Network makes diagnostics move

Current strategies for the treatments for obesity include diets, exercise, behavioral lifestyle changes, pharmaco-therapeutic agents and bariatric surgery.53, 54 T therapy is another novel approach to treatment of obesity, as it reduces fat mass and improves lean body mass. This is of critical importance, as balance in the body composition relates to metabolic function.55 We believe that T therapy represents a novel pharmaco-therapeutic approach in the treatment of underlying patho-physiological conditions of obesity. We should also point out that treatment adherence is a major concern in managing chronic diseases such as obesity. We report that adherence and compliance to T therapy with TU 3-monthly injections was remarkable in previous studies.

A total of 147 hypogonadal men from 38 to 83 years of age participated in the study, all of whom had presented at a urology clinic with testosterone levels between 0.14 and 3.51 ng/mL. It can also be used to treat clinical symptoms such as regression of secondary sexual characteristics, change in body composition, asthenia, reduced libido or erectile dysfunction. “The majority of us who really keep up on these data are supportive of the concept that testosterone is beneficial in appropriately selected patients,” Dr Trost said. “But that’s not a man with normal testosterone who just wants a boost in life; it’s men with low-testosterone symptoms and consistently low testosterone values who are most likely to benefit significantly from treatment.” “We need to do our best to convince healthcare professionals and the authorities that testosterone is actually a very beneficial treatment that confers many health benefits on these men, including less cardiovascular disease and fewer cardiovascular events,” he explained. One in six men over 50 have symptoms of testosterone deficiency, but too few of them receive appropriate treatment, said Grünenthal CEO Gabriel Baertschi.

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Join over 187,400 biopharma colleagues who rely on Endpoints News every business day for the latest developments in drug discovery, development, and commercialization. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news. Grünenthal has invested over €2 billion in successful M&A transactions over the last several years.

The formulation of TU in tea seed oil (in China) and castor oil (in Germany) for intramuscular use has yielded longer acting testosterone depots with more favorable pharmacokinetics. TU alone (tea seed oil) was found to induce azoospermia in 96% (23/24) of Asian men (500 or 1000 mg in tea seed oil every 4 weeks) and in 57% (8/14) of Caucasian men (1000mg in castor oil every 6 weeks) studied. Phase III contraceptive efficacy trials using TU alone are in progress in China. A combination of TU with a progestogen has been studied in Caucasian subjects (see Table I). DMPA (depot medroxyprogesterone acetate) was administered by a single im injection.

In this study, only one patient was dropped out in 8 years, due to moving to a new geographical location. T therapy produced sustained WL without recidivism.35, 36, 38 It is possible that T therapy in obese men with TD may prove useful in treatment of the underlying patho-physiological conditions of obesity. In this report, we summarize our findings on long-term T therapy in men with TD with varying classes of obesity. The data presented suggest significant improvement in WL, reduction in WC and BMI.

A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Couples agree that Levitra(R) provided significantly greater satisfaction versus placebo and that satisfaction is achieved by not only to the man, but also to his partner. Additionally, there was a “marked reduction” in C-reactive protein levels over the 4-year period, from 7.1 to 1.6 mg/L, which was not surprising because “testosterone has recently been shown in a number of studies to be an anti-inflammatory agent,” he said. There was also an initial significant decrease in levels of liver enzymes, with aspartate aminotransferase dropping from 43.9 to 22.0 U/L and alanine aminotransferase dropping from 46.6 to 22.8 U/L over the first 24 months, and then leveling off. These decreases likely indicate an improvement of nonalcoholic fatty liver disease, said Dr. Saad. He said it is possible that cholesterol levels improved with the help of other medications.

Join the ConversationLeave a reply

Your email address will not be published. Required fields are marked *

Comment*

Name*

Website